Home › Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies
 

Keywords :   


Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies

2014-09-03 11:37:54| drugdiscoveryonline Home Page

Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)

Tags: with advanced corporation agent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »